Arca
Skip to content
Tools
Tools

Spinal cord injury

Drug research and approvals for spinal cord injury: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 379 studies of spinal cord injury are recruiting on ClinicalTrials.gov, Health Canada has authorized 8 drug trials for it since 2013, and FDA has 2 approved and 17 open orphan designations naming it.

  • Recruiting worldwide: 379
  • Trials authorized in Canada: 8
  • FDA orphan approvals: 2
  • EU medicines: 0

Recruiting now

Newest posted first, of 379 recruiting on ClinicalTrials.gov ↗

How its trials ended

1,704 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 255 whose ending is known, 36% met their primary endpoint, 5% missed it and 59% stopped early.

  • Completed, result not reported73543%
  • Ongoing47728%
  • Status unknown23714%
  • Stopped: other or unclear946%
  • Met its primary endpoint915%
  • Stopped: enrollment or feasibility272%
  • Stopped: funding151%
  • Missed its primary endpoint131%
  • Stopped: sponsor or business decision101%
  • Stopped: lack of efficacy5<1%

Trials authorized in Canada

Newest first; search them all in Canada trials
Sep 10, 2026A trial investigating the efficacy and safety of nvg 291 in subjects with chronic spinal cord injury - a randomized, double-blind, placebo-controlled…NVG-291Nervgen Pharma Corp.Pending
Mar 11, 2025Low oxygen therapy as a cardiac treatment for improving 24-hour blood pressure stability in spinal cord injuryOxygen/ Nitrogen/ Carbon dioxideUniversity of British Columbia, School of Health and Exercise SciencePending
Dec 22, 2022Effects of the serotonin precursor, 5-hydroxytryptophan (5-htp), on the injured human spinal cordCarbidopaGovernors of The University of AlbertaOngoing
Oct 7, 2021Can brief exposure to hyperoxia improve function after chronic spinal cord injury?Oxygen/ Oxygen-nitrogenGovernors of The University of AlbertaOngoing
Feb 24, 2021A phase 2a,randomized, double-blind, placebo-controlled study to assess the efficacy and safety of MT-3921 in subjects with acute traumatic cervical spinal…MT-3921Mitsubishi Tanabe PharmaPending
Dec 17, 2019A randomized, double-blind, placebo-controlled proof of concept study to assess the safety and efficacy of elezanumab in acute traumatic cervical spinal cord…Elezanumab (ABT-555)AbbVieClosed
Sep 11, 2019Effects of baclofen on presynaptic inhibition in humansBaclofenGovernors of The University of AlbertaOngoing
Apr 15, 2016A phase 2b/3, double-blind, randomized, placebo controlled, multicenter study to assess the efficacy and safety of VX-210 in subjects with acute traumatic…VX-210 / TisseelVertex PharmaceuticalsOngoing

FDA orphan designations

Approved first, then open designations, newest first; 15 of 19
Sep 18, 2019OzobaxTreatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and…Metacel Pharmaceuticals, LLCApproved
Jun 25, 1992Lioresal IntrathecalManagement of severe spasticity of spinal cord origin in patients who are unresponsive to oral baclofen therapy or experience intolerable…Medtronic, Inc.Approved
Jul 14, 2025FGFR and ITGB1 agonist peptide amphiphile scaffoldTreatment of acute spinal cord injuryAmphix BioDesignated
Jun 10, 2025Oremepermin alfaTreatment of acute spinal cord injuryKringle Pharma, Inc.Designated
Oct 26, 2023Mesenchymal stem cell (MSC) derived small extracellular…Treatment of Acute Spinal Cord InjuryNurExone Biologic, Ltd.Designated
Nov 20, 2018Humanized connexin 43 monoclonal antibodyTreatment of acute spinal cord injuryAlaMab Therapeutics, Inc.Designated
Feb 2, 2016Oligodendrocyte progenitor cellsTreatment of acute spinal cord injuryLineage Cell Therapeutics, Inc.Designated
Sep 29, 2015GlyburideTreatment of acute spinal cord injuryRemedy Pharmaceuticals, Inc.Designated
Dec 3, 2012Porcine GM1 gangliosideTreatment of acute spinal cord injuryTRB Chemedica International S.A.Designated
Feb 1, 2008Autologous olfactory neural progenitorsTreatment of spinal cord injury patients with ASIA Impairment grades A, B, or CRhinoCyte, Inc.Designated
Nov 18, 2005Recombinant deriative of C3 transferaseTreatment of acute spinal cord injuryVertex Pharmaceuticals, Inc.Designated
Jul 7, 2005Contulakin-GIntrathecal treatment of neuropathic pain associated with spinal cord injuryCognetix, Inc.Designated
Apr 26, 2005L-threonyl-L-prolyl-L-prolyl-L-threonineTreatment of neuropathic pain associated with spinal cord injuryNyxis Neurotherapies, Inc.Designated
Sep 3, 2004Autologous incubated macrophageTherapy to improve the motor and sensory neurological outcome in acute cases of spinal cord injuryProneuron Biotechnologies, Inc.Designated
Mar 12, 2002AlbuterolPrevention of paralysis due to spinal cord injuryMotoGen, Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.